Nodality Raises Series A Financing
South San Francisco, CA, February 1, 2007Nodality, Inc., a biotechnology company focused on the development of next generation personalized medicine tests in cancer and autoimmune disease, today announced it has raised $11.1 million in Series A financing, with proceeds from Kleiner Perkins Caulfield & Byers and TPG Biotechnology.
Nodality is pleased to announce that Risa Stack, Ph.D., a partner in Kleiner Perkins Caulfield and Byers, and Fred Cohen, M.D., Ph.D., partner and managing director of TPG Biotechnology have joined the company's Board of Directors.
Nodality utilizes proprietary Single Cell Network Profiling (SCNP) technology to characterize signaling pathways in cancer and autoimmune diseases in order to develop and commercialize highly predictive clinical tests, and to reduce time, cost, and risks of drug development. Unique aspects of Nodality's proprietary technology include the fact that complex intracellular signaling networks are characterized at the individual living cell level.
About NodalityNodality is a private, South San Francisco-based biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling technology platform. Through its ability to functionally characterize cell signaling networks at the single cell level of resolution Nodality is committed to the biological characterization of individual patients to optimally match them with biologically-targeted treatments.
About Single Cell Network ProfilingSingle Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signalling networks in patients with cancer and autoimmune diseases. SCNP, by measuring functional signaling network behavior in single cells, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of cellular heterogeneity including the importance of rare cells such as drug-resistant and stem cells. As the technology has widespread application in both preclinical and clinical drug development, Nodality is also utilizing SCNP in collaboration with drug developers to decrease the time, cost, and risks of drug development.